Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species
Human Annexin a1 ELISA Kit for Sandwich ELISA - ABIN415284
Sena, Grishina, Thai, Goulart, Macal, Fenton, Li, Prindiville, Oliani, Dandekar, Goulart, Sankaran-Walters: Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease. in PLoS ONE 2013
Show all 4 Pubmed References
Mouse (Murine) Annexin a1 ELISA Kit for Sandwich ELISA - ABIN427785
Rackham, Vargas, Hawkes, Amisten, Persaud, Austin, King, Jones: Annexin A1 Is a Key Modulator of Mesenchymal Stromal Cell-Mediated Improvements in Islet Function. in Diabetes 2015
Show all 2 Pubmed References
Rabbit Annexin a1 ELISA Kit for Sandwich ELISA - ABIN1450259
Krel, Petraitis, Petraitiene, Jain, Zhao, Li, Walsh, Perlin: Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response. in Antimicrobial agents and chemotherapy 2014
Data indicate a regulatory circuit between ANXA1, NF-kB, c-myc (show MYC ELISA Kits) and miR (show MLXIP ELISA Kits)-196a which regulates breast cancer cell proliferation and tumor growth.
In colorectal cancer, miR (show MLXIP ELISA Kits)-196a over-expression was negatively correlated with annexin A1 protein expression (r = -0.738, p < 0.001), and both were indicators of unfavorable prognosis in terms of poor differentiation, larger tumor size, and advanced clinical stage
The data of this study supported a potential role of ANXAl in AD by reducing Abeta (show APP ELISA Kits) levels and decreasing neuroinflammation, suggesting a novel view that ANXAl may play a protective role in AD progression.
these data indicate that AnxA1 is actively expressed during L. braziliensis infection.
Data, including data from studies using knockout mice, suggest cAMP-elevating agents increase levels of ANXA1; this is involved in role of cAMP in resolving acute inflammation (here, ability of cAMP-elevating agents to treat LPS (show IRF6 ELISA Kits)-induced neutrophilic pleurisy). These results reinforce hypothesis that ANXA1 acts in multiple cell types (neutrophils, macrophages) and at multiple levels to promote resolution of inflammation.
Circulating IgG antibodies to ANXA1 could be used as a biomarker for early diagnosis of non-small cell lung carcinoma.
Down-regulation of Annexin A1 in nasopharyngeal carcinoma may lead to the overexpression of S100A9 (show S100A9 ELISA Kits)/Vimentin (show VIM ELISA Kits), which may increase the possibility of the invasion ability of NPC (show NPC1 ELISA Kits) cells by adjusting the function of cytoskeleton proteins.
ANXA1 is down-regulated and differentially expressed within the SCD (show SCD ELISA Kits) genotypes
Annexin A1-regulated contacts function in the transfer of endoplasmic reticulum-derived cholesterol to the multivesicular endosomes/bodies when low-density lipoprotein-cholesterol in endosomes is low.
This review explores the diverse actions of annexin A1 on breast tumor cells and various host cell types, including stromal immune and structural cells, particularly in the context of cancer immunoediting. [annexin A1]
Data suggest amino acid substitution in ANXA1 (S27E; S27A (show RPS27A ELISA Kits)) at site of post-translational phosphorylation affects protein stability, core domain calcium binding affinity, core domain/N-terminal domain structures, and N-terminal domain orientation.
annexin I is regulated by an anti-apoptotic Bcl-2 (show BCL2 ELISA Kits) protein in Tumor Necrosis Factor-alpha (show TNF ELISA Kits)-induced renal apoptotic events
Calves that later developed pneumonia had significantly lower levels of annexin A1 and annexin A2 (show ANXA2 ELISA Kits), which are potential biomarkers of increased susceptibility to pneumonia in recently weaned and transported feedlot cattle.
Ubiquitination of annexin A1 may play an important role in mutagenesis, an initial step of cell transformation.
Because annexins I and II are abundant and have functions important to the maintenance of placentation, the down-regulation of the annexin genes in the cultured NT (nuclear transfer)trophectoderm may be related to the frequent failures of NT pregnancies.
The present findings shed light on the role of GILZ (show TSC22D3 ELISA Kits) in the mechanism of induction of Anxa1 by GCs (show UGCG ELISA Kits). As Anxa1 is an important protein for the resolution of inflammatory response, GILZ (show TSC22D3 ELISA Kits) may represent a new pharmacologic target for treatment of inflammatory diseases.
Data, including data from studies using knockout mice, suggest cAMP-elevating agents increase levels of AnxA1; this is involved in role of cAMP in resolving acute inflammation (here, ability of cAMP-elevating agents to treat LPS (show TLR4 ELISA Kits)-induced neutrophilic pleurisy). These results reinforce hypothesis that AnxA1 acts in multiple cell types (neutrophils, macrophages) and at multiple levels to promote resolution of inflammation.
confirmed the ability of Plg (show PLG ELISA Kits)/Pla to both promote efferocytosis and override the prosurvival effect of LPS (show TLR4 ELISA Kits) via annexin A1.
this study shows that AnxA1 plays a crucial role in the context of acute gouty inflammation by promoting timely resolution of inflammation
Suggest protective role for Annexin A1 in arterial neointima formation in atherosclerosis-prone mice.
ANXA1 restores Abeta42-induced blood brain barrier disruption through inhibition of RhoA (show RHOA ELISA Kits)-ROCK signaling pathway
Here, we provide a new anti-inflammation mechanism about ANXA1 secreted from injured IECs, where ANXA1 can stimulate the expression of NKG2A (show KLRC1 ELISA Kits) in NK cells that affect the recruitment and activity of neutrophils necessary for pathology of colitis.
It is proposed that the interactions between ANXA1 and GATA-3 (show GATA3 ELISA Kits) may provide clues to understand the immunosuppression and have potential as new therapeutic targets in immunotherapy after sepsis.
AnxA1, is related to the efficiency of the infliximab treatment in experimental colitis, constituting a potential biomarker of therapeutic efficacy
Annexin I belongs to a family of Ca(2+)-dependent phospholipid binding proteins which have a molecular weight of approximately 35,000 to 40,000 and are preferentially located on the cytosolic face of the plasma membrane. Annexin I protein has an apparent relative molecular mass of 40 kDa, with phospholipase A2 inhibitory activity. Since phospholipase A2 is required for the biosynthesis of the potent mediators of inflammation, prostaglandins and leukotrienes, annexin I may have potential anti-inflammatory activity.
, ANX Ia
, annexin 1a
, lipocortin 1
, Annexin A1
, annexin A1-like
, annexin I (lipocortin I)
, calpactin II
, lipocortin I
, phospholipase A2 inhibitory protein
, annexin I
, Annexin 1 (p35) (Lipocortin 1)
, calcium-dependent membrane binding protein annexin I